INVO refocuses on fertility after NTI sale; heavy impairments, tight cash

INVO Fertility, Inc. (PINK: INVO) - Quick take
The company has refocused on fertility operations after divesting an 80.1% stake in NAYA Therapeutics (NTI). Results show modest revenue growth but a large, non‑cash hit from impairments and heavy financing activity - cash is tight and management discloses material weaknesses and a going‑concern qualification risk.

What's happening inside
* Strategic refocus: divested majority of NTI on June 2, 2025 and returned to an exclusive fertility focus.
* Clinic push: operating two INVO Centers + Wisconsin Fertility Institute; clinic revenue is the main driver.
* Active capital activity: January 2025 public offering (~$8.7M net), preferred conversions and multiple amendments/exercises with key investor FNL (Series C‑2 activity).

Key facts & figures (as reported)
* Cash (June 30, 2025): $549,181.
* Total assets: $19,319,239; Total liabilities: $16,687,766; Stockholders' equity: $2,631,473.
* Cash and shares: company reported 4,363,016 shares outstanding as of August 14, 2025 (filing cover).
* Six months ended June 30, 2025 - Total revenue: $3,500,839 (Clinic revenue $3,453,647; Product $47,192).
* Six months net loss: $22,688,444; three months net loss (Q2): $5,284,858.
* Loss from discontinued operations (NTI) - six months: $16,452,562 (includes goodwill impairment).
* Impairment loss (continuing + discontinued): $16,042,422 (includes $14,645,069 goodwill impairment on NTI).
* Accumulated deficit: $(90,203,241).
* Loss per share, six months (basic): $(75.85); three months (basic): $(13.30).
* Weighted average shares (six months): 299,114; (three months) 397,440.
* Accounts receivable: $242,255; Inventory: $212,611; Prepaids & other current assets: $395,306.
* Convertible notes payable - current portion, net: $2,888,947; Notes payable, net of current: $1,041,492.
* Note receivable (NTI promissory note): $4,803,175 (7% interest; matures Nov 28, 2026).
* Additional payments for acquisition - current portion: $5,000,000; non‑current: $1,125,000.
* Net cash used in operating activities (six months): $(5,263,155); Net cash provided by financing: $5,101,036.

Positive items
* Revenue holding up: six‑month revenue up slightly to $3.50M from $3.41M YoY; clinic revenue grew to $3.45M.
* Capital raised: Jan 2025 public offering net proceeds ~$8.7M provided liquidity and enabled partial debt/preferred redemption.
* Balance sheet actions: active debt restructures and preferred exchanges with FNL provided runway options (Amended & Restated Debenture; AIR arrangements).
* Reduced cash burn from some SG&A line items: SG&A decreased versus prior periods (non‑cash stock comp also down YoY).

Negative / risk items
* Large net loss and impairments: $22.7M loss for six months driven largely by NTI goodwill and related impairments plus disposal losses - heavy non‑cash but material to earnings.
* Discontinued operations drag: $16.45M loss on NTI substantially widens the headline loss.
* Liquidity stressed: only $549k cash on hand at 6/30/25, negative working capital (~$6.3M cited), operating cash burn $(5.3M) in six months - company says it will need to raise more capital.
* High leverage & near‑term payables: large current liabilities (total current liabilities $12.46M), convertible debt and acquisition‑related payment obligations (current $5.0M).
* Equity dilution risk: aggressive use of convertible instruments, preferred conversions and warrant issuances - weighted shares and outstanding common share count have risen materially since prior periods.
* Governance / controls: management reports material weaknesses in internal controls and limited accounting resources - increases audit & execution risk.
* Going concern: auditors previously expressed substantial doubt about ability to continue as a going concern; management acknowledges need for additional financing.

Analyst view - concise implications
* Operationally the fertility clinics provide a steady revenue base and modest growth; the INVOcell product line remains small but complementary.
* The large losses are mostly non‑cash impairment and the NTI divesture; however, cash flow remains the central issue - the company depends on financing activity to remain solvent.
* Watch: upcoming required acquisition payments ($5.0M current piece), convertible debenture maturities/amendments, further exercises of Series C‑2 (conversion price drift), and any missed settlement payments tied to the WFI settlement schedule.
* Catalysts / downside: successful clinic acquisitions and improved operating cash generation could stabilize the story; failure to raise capital or further adverse legal/settlement outcomes could force deeper dilution or restructuring.

Bottom line: INVO (PINK: INVO) is a small, liquidity‑constrained fertility operator that has cleaned up a biotech distraction (NTI) but recorded large impairment and disposal losses. Revenue from clinics is steady, financing activity has kept it alive, but cash and internal control issues make this a high‑risk, turnaround‑dependent situation. Monitor cash runway, debt milestones, FNL exercises, and the WFI settlement payment schedule closely.